SBDM 012
Alternative Names: SBDM-012Latest Information Update: 02 Jan 2023
At a glance
- Originator Shilpa Biologicals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Chronic lymphocytic leukaemia
Most Recent Events
- 05 Dec 2022 Early research in Chronic lymphocytic leukaemia in India (unspecified route) (Shilpa Biologicals pipeline, December 2022)